Gettinger K, Lee D, Tomita Y, Negishi K, Kurihara T. Diabetic Retinopathy, a Comprehensive Overview on Pathophysiology and Relevant Experimental Models. Int J Mol Sci. 2025;26(20):9882. https://doi.org/10.3390/ijms26209882.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dietrich L, Lucius R, Roider J, Klettner A. Interaction of inflammatorily activated retinal pigment epithelium with retinal microglia and neuronal cells. Exp Eye Res. 2020;199:108167. https://doi.org/10.1016/j.exer.2020.108167.

Article  CAS  PubMed  Google Scholar 

Alemán-González-Duhart D, Tamay-Cach F, Álvarez-Almazán S, Mendieta-Wejebe J. Current advances in the biochemical and physiological aspects of the treatment of type 2 diabetes mellitus with thiazolidinediones. Pharmacol Res. 2016;2016:7614270. https://doi.org/10.1155/2016/7614270.

Article  CAS  Google Scholar 

Das A, Stroud S, Mehta A, Rangasamy S. New treatments for diabetic retinopathy. Diabetes Obes Metab. 2015;17(3):219–30. https://doi.org/10.1111/dom.12413.

Article  CAS  PubMed  Google Scholar 

Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4. https://doi.org/10.2174/1874364101307010004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steinmetz JD, Bourne RRA, Briant PS, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years. Lancet Glob Health. 2021;9(2):e144–60. https://doi.org/10.1016/S2214-109X(20)30489-7.

Article  Google Scholar 

Valdez-Guerrero AS, Quintana-Pérez JC, Arellano-Mendoza MG, Castañeda-Ibarra FJ, Tamay-Cach F, Alemán-González-Duhart D. Diabetic retinopathy: important biochemical alterations and the main treatment strategies. Can J Diabetes. 2021;45(6):504–11. https://doi.org/10.1016/j.jcjd.2020.10.009.

Article  PubMed  Google Scholar 

Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive versus conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;6CD008143. https://doi.org/10.1002/14651858.CD008143.pub2.

Hammes HP, Welp R, Kempe HP, et al. Risk factors for retinopathy and DME in type 2 diabetes. PLoS ONE. 2015;10(7):e0132492. https://doi.org/10.1371/journal.pone.0132492.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammes HP, Kerner W, Hofer S, et al. Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients. Diabetologia. 2011;54(8):1977–84. https://doi.org/10.1007/s00125-011-2198-4.

Article  CAS  PubMed  Google Scholar 

Liu L, Yue S, Wu J, et al. Prevalence and risk factors of retinopathy in patients with or without metabolic syndrome: a population-based study in Shenyang. BMJ Open. 2015;5(12):e008855. https://doi.org/10.1136/bmjopen-2015-008855.

Article  PubMed  PubMed Central  Google Scholar 

Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Proteome analysis of retinal glia-related inflammatory cytokines in the aqueous humour of diabetic patients. Acta Ophthalmol. 2016;94(1):56–64. https://doi.org/10.1111/aos.12825.

Article  CAS  PubMed  Google Scholar 

Phillips K, Kilburn TC, Penn JS, Uddin MI. Molecular imaging of retinal hypoxia in diabetic mouse models. Invest Ophthalmol Vis Sci. 2020;61(7):3732. https://doi.org/10.1167/iovs.61.7.3732.

Article  Google Scholar 

Ishibazawa A, Nagaoka T, Yokota H, et al. Characteristics of retinal neovascularization in proliferative diabetic retinopathy imaged by optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57(14):6247–55. https://doi.org/10.1167/iovs.16-20494.

Article  PubMed  Google Scholar 

Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799. https://doi.org/10.1016/j.redox.2020.101799.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yudistira Y, Hendrawan KA, Andayani A, Suryathi NMA. Diabetic retinopathy: pathogenesis, pathophysiology, and treatment. Universa Med. 2025;44(2):270–84. https://doi.org/10.18051/UnivMed.2025.v44.270-284.

Article  CAS  Google Scholar 

Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279–91. https://doi.org/10.1016/j.cell.2014.03.065.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37(5):571–9. https://doi.org/10.1038/aps.2016.40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017;41(1):112–9. https://doi.org/10.1038/ijo.2016.191.

Article  CAS  PubMed  Google Scholar 

Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32(6):755–97. https://doi.org/10.1210/er.2010-0027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maj M, Hernik K, Tyszkiewicz K, Owe-Larsson M, Malejczyk J, Janiuk I. A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections. Front Immunol. 2025;16:1567874. https://doi.org/10.3389/fimmu.2025.1567874.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebert A, König J, Frommer L, Schuppan D, Kahaly GJ. Chromogranin serves as a novel biomarker of endocrine and gastric autoimmunity. J Clin Endocrinol Metab. 2020;105(8):2606–15. https://doi.org/10.1210/clinem/dgaa288.

Article  Google Scholar 

Herold Z, Herold M, Nagy P, Patocs A, Doleschall M, Somogyi A. Serum chromogranin A level continuously rises with the progression of type 1 diabetes. J Diabetes Investig. 2020;11(4):865–73. https://doi.org/10.1111/jdi.13203.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muntjewerff EM, Epremidze D, Nezhyva M, Kal S, Rohm TV, Tang K, Christoffersson G. Chromogranin A and catestatin regulate pancreatic islet homeostasis, endocrine function, and neurotransmitter signaling. Commun Biology. 2025;8(1):1684. https://doi.org/10.1038/s42003-025-09135-z.

Article  CAS  Google Scholar 

Nadri G, Saxena S, Mahdi AA, et al. Serum vitamin D is a biomolecular biomarker for proliferative diabetic retinopathy. Int J Retina Vitreous. 2019;5:31. https://doi.org/10.1186/s40942-019-0181-z.

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Kang YE, Kim JM, et al. Serum meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract. 2018;135:7–10. https://doi.org/10.1016/j.diabres.2017.10.005.

Article  CAS  PubMed  Google Scholar 

Güngör Kobat S, Gül FC, Çelik F, et al. Plasma and aqueous levels of subfatin, preptin and betatrophin in patients with diabetic retinopathy. BMC Endocr Disord. 2023;23(1):312. https://doi.org/10.1186/s12886-023-03075-0.

Article  CAS  Google Scholar 

Hassan HJ, Mohammad TU, Hameed EK. The elevation of serum subfatin levels in patients with double diabetes. J Sports Sci Food Sci. 2023;10(3S):5479–87.

Google Scholar 

Görgens SW, Eckardt K, Jensen J, Drevon CA, Eckel J. Exercise and regulation of adipokine and myokine production. Prog Mol Biol Transl Sci. 2015;135:313–36. https://doi.org/10.1016/bs.pmbts.2015.07.002.

Article  PubMed  Google Scholar 

Herold Z, Doleschall M, Kövesdi A, Patócs A, Somogyi A. Chromogranin A and its role in the pathogenesis of diabetes mellitus. Endocr Pract. 2018;69(5):598–610. https://doi.org/10.5603/EP.a2018.0052.

Article